PT-141 (Bremelanotide) research guide for Beigem. Melanocortin-4 receptor agonist studied for sexual function — covers purity standards, COA testing, and sourcing.
PT-141 (Bremelanotide) isn't stocked on pharmacy shelves in Beigem or virtually any local market — it's a research-grade peptide available through a dedicated online market. This global online supply model is a genuine benefit for researchers — top vendors distinguish themselves through rigorous testing in ways brick-and-mortar outlets simply cannot. Separating properly characterised PT-141 (Bremelanotide) from the rest of the market depends on three things: an HPLC chromatogram confirming ≥98% purity, mass spec data establishing the correct molecular weight, and a batch-specific endotoxin panel. Use this guide to assess sourcing options methodically — the standards covered in this guide work regardless of your location.
PT-141 (Bremelanotide) falls within a class of peptides studied for dermatological and aesthetic biology applications. GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is one of the most extensively studied cosmetic peptides, with documented activity in promoting collagen I and collagen III synthesis in fibroblast cultures, activating antioxidant enzymes, and promoting wound healing. Its copper-chelating properties make it mechanistically distinct from non-metallopeptides in the aesthetic category. Melanotan-2 (MT-2) is a cyclic analogue of alpha-melanocyte-stimulating hormone (α-MSH) that acts on melanocortin receptors — primarily MC1R in melanocytes for pigmentation effects and MC4R in the hypothalamus for other documented effects. For researchers in Beigem studying skin biology, pigmentation, or melanocortin receptor pharmacology, these compounds offer mechanistically specific research tools.
PT-141 (Bremelanotide) Purchasing Guide
The first step for any Beigem researcher sourcing PT-141 (Bremelanotide) is finding vendors with verified community track records — organic rankings are no guide to actual PT-141 (Bremelanotide) quality. Mass spectrometry in the COA confirms that the main HPLC peak is actually PT-141 (Bremelanotide) and not a different peptide of similar polarity — HPLC purity alone does not confirm what the compound actually is. Signs of a credible vendor beyond COA quality: documented vendor history spanning multiple years, responsive technical support who understand testing methodology, and shipping with desiccant and appropriate cold protection. Bacteriostatic water is the standard reconstitution medium for PT-141 (Bremelanotide) — it contains 0.9% benzyl alcohol that inhibits bacterial growth and extends reconstituted shelf life to 4 weeks when kept refrigerated.
Order PT-141 (Bremelanotide) — ships to Beigem
COA-verified · International tracking · Research grade
PT-141 (Bremelanotide) is available for research use only and is not approved for human use by the FDA or comparable health authorities — all information here is provided for educational purposes. Temperature excursions — even brief warming above recommended storage temperature — can partially degrade PT-141 (Bremelanotide) without visible changes; always use only material shipped with appropriate cold protection. Verify the endotoxin level in your PT-141 (Bremelanotide) batch COA before any injectable research application — look for results stated as EU/mg and verify they are within the acceptable range for your research context. PubMed represent the most comprehensive research databases for PT-141 (Bremelanotide) research; focus on peer-reviewed publications with documented compound quality over conference abstracts or single case observations.
Frequently Asked Questions
How does PT-141 differ from Melanotan-2?
Both are melanocortin receptor agonists, but PT-141 is more selective for MC3R/MC4R (CNS-expressed receptors) while MT-2 has broader activity including MC1R (melanocytes) for pigmentation. PT-141 was specifically developed from MT-2 to have the CNS effects with reduced pigmentation side effects.
What is PT-141?
PT-141 (Bremelanotide) is a cyclic melanocortin receptor agonist developed from Melanotan-2. Unlike MT-2, PT-141 acts primarily on MC3R and MC4R receptors in the CNS rather than MC1R in melanocytes. It received FDA approval in 2019 as Vyleesi for hypoactive sexual desire disorder in premenopausal women. As a research compound it is studied for melanocortin receptor pharmacology.
What is the regulatory status of PT-141?
PT-141 (as Bremelanotide/Vyleesi) is an FDA-approved pharmaceutical in the US for HSDD in premenopausal women. This pharmaceutical status means it is more tightly regulated than pure research compounds in most jurisdictions. Import and possession regulations vary by country — verify current status in your jurisdiction before ordering.
